mechanisms for medium inventions, and patent their most important innovations. This result reestablishes the traditional view …

In 2004 the German Patent and Trademark Office commissioned the Ifo Institute to deliver a research report on the topic … "Identification of Available and Desirable Indicators for Patent Systems, Patenting Processes and Patent Rights". - The report … but also giving consideration to legal and business aspects. This includes the valuation of the patent system itself, the …

adapt to the new international rules on patent law. One of the main points of the Agreement is the possibility of …

public interest aspect and human rights implications while granting injunctions in patent litigation. Moreover, it asserts … that the courts should exercise prudence in granting injunctive relief in cases involving patent infringement, and take …

into the national patent law the concept of humanitarian compulsory licensing. …

strengthening the use of preventive and remedial TRIPS flexibilities and removing criminal sanctions for patent infringements …. Cambodia should reject any TRIPS-plus provisions in its patent legislation and avoid membership in bilateral or plurilateral … trade agreements that include TRIPS-plus provisions as well as signing patent treaties and memorandums of understanding that …

to provide latitude to the Member States to tailor their national patent laws to fit their individual needs. In 2001, the … the lead role in enacting the TRIPS Agreement's substantive and procedural patent flexibilities by introducing unique … compulsory licensing, the most notable exception to patent rights provided under the TRIPS Agreement. This empirical study is …

prevention of COVID-19. The aim of the report is to support national patent offices and interested parties in developing … countries with information that can serve as guidance for the examination of the claims contained in relevant patents or patent … applications. The antibody combination considered for the patent analysis in this paper are Casirivimab and Imdevimab. The vaccines …